<DOC>
	<DOCNO>NCT00378365</DOCNO>
	<brief_summary>To assess role Arsenic trioxide and/or ATRA consolidation course APL . It hop investigational arm increase event-free survival 2 year , reduce toxicity without increase relapse rate comparison classical anthracycline-AraC consolidation regimen .</brief_summary>
	<brief_title>Acute Promyelocytic Leukemia 2006 ( APL )</brief_title>
	<detailed_description>Definition : Extended description protocol , include information already contain field , comparison ( ) study . APL specific type acute myeloid leukemia ( AML ) characterize morphology ( M3 M3v FAB classification ) , ( 15 ; 17 ) translocation lead PML-RARa fusion gene , specific coagulopathy combine D.I.C. , fibrinolysis non specific proteolysis . ATRA differentiate APL blast VITRO vivo . The combination ATRA anthracycline base chemotherapy yield CR rate great 90 % newly diagnose APL . With early introduction anthracycline AraC chemotherapy induction treatment , maintenance combine continuous 6MP MTX intermittent ATRA , relapse risk APL therefore appear range 10 15 % . Nevertheless , 5 10 % patient achieve CR 10 % 15 % still relapse . Another subset patient ( 5 7 % APL 93 trial include 17 % patient age great 65 year ) die CR , complication consolidation treatment phase , mainly infection chemotherapy induce aplasia . Failure achieve CR current treatment approach almost exclusively due early death induction treatment . Causes death predominantly bleed , ATRA syndrome less often infection . Early death predominate elderly patient patient high WBC count . Reducing amount chemotherapy administer newly diagnose APL patient diminish toxicity . The Spanish PETHEMA group report result two successive phase II trial newly diagnose APL ATRA chemotherapy intercalate agent ( idarubicin mitoxantrone ) without AraC follow maintenance combine ATRA low dose chemotherapy ( LPA96 LPA99 trial ) . Results appear similar best arm APL 93 trial , less toxicity 2 3 % death CR see , include elderly patient . Arsenic trioxide ( As2O3 ATO ) effective agent relapse refractory APL , induce 85 % hematological 79 % molecular CR rate pivotal US study . The interest ATO front-line therapy newly-diagnosed APL strongly suggest three study show high complete remission rate , low incidence relapse limited toxicity . In study , patient stratify base age ( ≤ 70 year &gt; 70 year ) WBC count diagnosis ( WBC &lt; 10.000/mm3 &gt; 10.000 /mm3 ) . -Patients age 70 year less WBC &lt; 10.000/mm3 . In population ( 70 % APL ) best treatment group APL2000 trial ( ATRA early introduction anthracycline-AraC chemotherapy Idarubicin substitute Daunorubicin , follow 2 anthracycline-AraC consolidation course maintenance combine continuous chemotherapy intermittent ATRA ) compare regimen , without AraC consolidation course replace : - either ATO - ATRA It hop investigational arm increase event-free survival 2 year , reduce toxicity without increase relapse rate comparison classical anthracycline-AraC consolidation regimen . - Patients age 70 year less WBC &gt; 10.000/mm3 Patients age 70 year less initial WBC count &gt; 10000/mm3 ( ie high count APL ) , represent 20 % APL , remain relatively high risk relapse even current reference treatment . The main objective study test addition ATO consolidation course current standard ATRA chemotherapy regimen . Patients receive best treatment group APL 2000 trial ( Idarubicin substitute Daunorubicin ) without ATO 2 consolidation cycle . - Patients older 70 year WBC &lt; 10.000 /mm3 . Elderly patient initial WBC ≤ 10000/m3 ( 8 % APL ) contra indication treatment receive regimen reduce cumulative dose chemotherapy addition ATO consolidation course first year maintenance treatment . The main purpose non randomize part trial reduce early death mortality death CR observe elderly patient , without increase relapse rate . - Patients older 70 year WBC &gt; 10.000 /mm3 . Elderly patient initial WBC &gt; 10000/m3 ( 2 3 % APL ) contra indication intensive regimen receive regimen low WBC moderate dos Aracytine induction first consolidation course . The main purpose non randomize part trial reduce early death mortality death CR observe elderly patient , without increase relapse rate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Diagnosis APL base morphological ground , confirm presence ( 15 ; 17 ) and/or PMLRARA rearrangement characterization bcr subtype ( PMLRAR characterization ) . Untreated patient . No contraindication intensive chemotherapy ( especially well documented cardiac contraindication idarubicin ) . In female patient : absence pregnancy adequate contraceptive method ( due teratogenetic effect ATRA early pregnancy ) . Absence Hypersensitivity Arsenic derivative . No QT interval prolongation complete atriaventricular block . Written informed consent . Patients already treat . Patients contraindication intensive chemotherapy , especially well documented cardiac contraindication Idarubicin . In female patient : pregnancy absence adequate contraceptive Methods QT interval prolongation complete atriaventricular block . Hypersensitivity Arsenic derivative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Acute promyelocytic leukaemia</keyword>
	<keyword>ATRA</keyword>
	<keyword>Idarubicin</keyword>
	<keyword>Arsenic trioxide</keyword>
	<keyword>Patient newly acute promyelocytic leukaemia ( APL )</keyword>
	<keyword>Unmapped MeSH term</keyword>
</DOC>